Lenalidomide and dexamethasone with or without clarithromycin in patients with multiple myeloma ineligible for autologous transplant: a randomized trial | Blood Cancer Journal
Bortezomib, lenalidomide, and dexamethasone with panobinostat for front-line treatment of patients with multiple myeloma who are eligible for transplantation: a phase 1 trial - The Lancet Haematology
Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement | Leukemia
BMS' Revlimid to get reimbursement as combo therapy for multiple myeloma < Pharma < Article - KBR
Maintenance Therapy with Revlimid for Multiple Myelom
Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma | NEJM
Long-Term Revlimid-Clarithromycin-Dexamethasone Is Effective And Safe In Newly Diagnosed Myeloma Patients
Revlimid 2.5mg Capsule
Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma - ScienceDirect
Revlimid Lenalidomide Capsule, 10 mg
Revlimid/ Dexamethasone : r/multiplemyeloma
Better quality of response to lenalidomide plus dexamethasone is associated with improved clinical outcomes in patients with relapsed or refractory multiple myeloma | Haematologica
Revlimid-Dexamethasone Combo Works in Some Difficult Myelomas
British Journal of Haematology | Wiley Online Library
Revlimid Full Prescribing Information, Dosage & Side Effects | MIMS Thailand
Aftermath of Revlimid of primary benefit multiple myeloma
Is the combination of Velcade, Revlimid, and dex (VRd) good myeloma patients over the age of 65? - YouTube
Revlimid - NPS MedicineWise
Carfilzomib/Lenalidomide/Dexamethasone → Lenalidomide Extended Dosing for Newly Diagnosed MM | Research To Practice
Better quality of response to lenalidomide plus dexamethasone is associated with improved clinical outcomes in patients with relapsed or refractory multiple myeloma | Haematologica
Multiple Myeloma Clinical Trials
Velcade/Revlimid/Dexamethasone New Standard for Newly Diagnosed Multiple Myeloma - CancerConnect
Lenalidomide, Bortezomib, and Dexamethasone Plus ASCT Delays Progression in Myeloma
Revlimid, Velcade and Dexamethasone (RVD)
A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma. - Abstract - Europe PMC
